WeVote
Log In

Bill

Bill

SJR 10

State Senate and House of Delegates Term Limits Amendment

2025 Regular Session Introduced by Mike Woelfel

Urges Congress to remove federal barriers and expand research into psychedelic-assisted therapies for PTSD, depression, TBI, and related conditions.

To Judiciary
0
WeVote Research Nonpartisan
Bill Summary · SJR 10

Summary — SJR 10

Urges Congress to take certain actions relating to the therapeutic use of certain psychedelic compounds (BDR R-801)

Purpose

SJR 10 is a non‑binding joint resolution urging the U.S. Congress and federal agencies to remove federal regulatory barriers and expand research into the therapeutic use of certain psychedelic/entheogenic compounds (examples named: psilocybin/psilocin, DMT, ibogaine, mescaline, MDMA). The resolution frames these substances as promising treatments for PTSD, treatment‑resistant depression, traumatic brain injury (TBI), substance use disorders and other mental health conditions, and it asks Congress to act to facilitate safe clinical access and study.

Key provisions / requests to Congress

The resolution asks Congress and appropriate federal agencies to:
- Increase federal funding for clinical and translational research into psychedelic‑assisted therapies.
- Create streamlined processes for approving and conducting research with these compounds (reducing regulatory burdens associated with Schedule I classification).
- Support compassionate medical use by allowing eligible investigational psychedelic drugs under Right to Try pathways, with appropriate safety protocols.
- Reschedule certain psychedelic compounds to a less restrictive DEA schedule to reduce barriers to clinical research and medical use.
- Provide legal protections from federal prosecution for individuals and entities that are complying with state and local laws concerning adult use of psychedelic compounds (amendments clarified language to reference compliance with state/local law and, in later versions, language about “supervised” adult use).
- Encourage state‑federal research partnerships to study public‑health outcomes of state programs.

The resolution also expresses Nevada’s support for expanding research at qualified in‑state institutions.

Who would be affected / potential impacts

  • Patients with PTSD, treatment‑resistant depression, TBI, chronic pain and substance use disorders (veterans and first responders are specifically highlighted).
  • Clinical researchers, academic medical centers, and treating clinicians who seek to run trials or provide supervised therapeutic services.
  • State programs that may implement regulated access frameworks and enter research partnerships with federal authorities.
  • Law‑enforcement and public‑health systems (the DHHS Working Group report presented to the Legislature found minimal community impact in jurisdictions with regulated programs).

Evidence and rationale cited

  • The resolution cites FDA Breakthrough Therapy designations (MDMA for PTSD; psilocybin for depression) and multiple Phase 2/3 trial outcomes. Amended text references specific trial outcomes cited in the bill: MDMA‑assisted therapy — ~67% of severe PTSD patients no longer meeting diagnostic criteria after treatment; psilocybin — ~75% response rate and 58% remission at 12 months for major depressive disorder. Testimony and the DHHS Psychedelic Medicines Working Group report (SB 242) are included as supporting material; some testimony (veteran patient, neurologist) recounts strong clinical improvements with ibogaine and psilocybin in individual cases and clinical studies.
  • The bill notes low abuse potential and favorable safety profiles when administered in controlled settings.

Procedural / timeline notes

  • Introduced in 2025 and, as reported, was enrolled and delivered to the Secretary of State (File No. 28). The measure passed and was amended during the 2025 legislative process (multiple committee actions, two reprints, and sponsor amendments to statistics and certain resolved clauses).
  • As a joint resolution, SJR 10 is a formal statement urging federal action; it does not itself change state criminal or regulatory law.

Fiscal / state impact

  • Legislative documents indicate no direct effect on state or local government finances from the resolution itself. The DHHS Working Group report (required by SB 242) and testimonies document research and program planning but do not impose expenditures through the resolution.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.